Promoted Content
Promoted Content

Find Clinical Drug Pipeline Developments & Deals by Tiziana Life Sciences

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Therapeutic Area filter
    Study Phase filter
      Country filter
        News Type filter
          Company filter
            refresh

            Companies By Therapeutic Area Full Screen

            Development Status Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Foralumab

            Therapeutic Area: Gastroenterology Product Name: TZLS-401

            Highest Development Status: Phase I/ Phase II Product Type: Large molecule

            Recipient: Parexel Biotech

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration November 11, 2020

            Details:

            This clinical study will evaluate the safety, tolerability, and clinical activity of escalating doses of orally administered capsules of Foralumab. The trial is a dose-ranging, open-label study that will enroll 60 patients in the U.S. and Europe.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Foralumab,Dexamethasone

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Phase I Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 02, 2020

            Details:

            Trial arranged in collaboration with Harvard Medical School and Dr. Howard Weiner. A patent application was filed in July 2020 to protect the potential use of nasally administered Foralumab to treat COVID-19 either alone or in combination with other anti-viral drugs.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): TZLS-501

            Therapeutic Area: Infections and Infectious Diseases Product Name: TZLS-501

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable August 24, 2020

            Details:

            United States Patent and Trademark Office has granted a patent for methods and use of fully human monoclonal antibody that recognizes both IL-6 receptor (IL-6R) and IL-6 receptor complex with IL-6 (IL-6R/IL-6) for prophylactic and therapeutic intervention for human diseases.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Foralumab

            Therapeutic Area: Gastroenterology Product Name: TZLS-401

            Highest Development Status: Undisclosed Product Type: Large molecule

            Partner/Sponsor/Collaborator: ThinkEquity

            Deal Size: $57.2 million Upfront Cash: Undisclosed

            Deal Type: Public Offering August 05, 2020

            Details:

            Tiziana intends to use the net proceeds to advance the clinical development of Foralumab, to initiate a trial in HCC patients with Milciclib, to expedite clinical development of TZLS-501 for coronavirus COVID-19, and for working capital and other general corporate purposes

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Foralumab,CAR-T Therapy

            Therapeutic Area: Oncology Product Name: TZLS-401

            Highest Development Status: Undisclosed Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable July 16, 2020

            Details:

            Tiziana has submitted a patent application on potential use of Foralumab, a fully human anti-CD3 monoclonal antibody (mAb), to improve success of CAR-T therapy for cancer and other human diseases.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): TZLS-501

            Therapeutic Area: Infections and Infectious Diseases Product Name: TZLS-501

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: STC Biologics

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement June 29, 2020

            Details:

            Tiziana's proprietary inhalation technology for direct delivery of mAbs or other small molecule drugs such as Remdesivir® (Roche) to lungs could potentially be a transformational therapy for developing a rapid treatment for COVID-19

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Dactinomycin

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Large molecule

            Recipient: Rasna Therapeutics

            Deal Size: $0.6 million Upfront Cash: $0.1 million

            Deal Type: Acquisition April 24, 2020

            Details:

            Actinomycin-D from Rasna Therapeutics will expand Tiziana Life Sciences's pipeline. The drug is on the WHO's List of Essential Medicines as the most effective medicines needed in a health system.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): TZLS-501

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable April 09, 2020

            Details:

            Development of this technology is a step forward toward expediting development of TZLS-501, for treatment of patients infected with COVID-19 (SARS-CoV-2) coronavirus.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): TZLS-501

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: ThinkEquity

            Deal Size: $10.0 million Upfront Cash: Undisclosed

            Deal Type: Public Offering March 12, 2020

            Details:

            Net proceeds to be used to advance the clinical development of Foralumab for Crohn’s Disease and M.S (ii) to expedite clinical development of TZLS-501 for coronavirus COVID-19.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): TZLS-501

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 11, 2020

            Details:

            Tiziana plans to administer TZLS-501 using a proprietary formulation technology. Tests have already shown that the treatment rapidly depletes circulating levels of IL-6 in the blood.

            PharmaCompass